Ironwood Pharmaceuticals Inc [IRWD] stock is trading at $5.23, down -2.97%. An important factor to consider is whether the stock is rising or falling in short-term value. The IRWD shares have gain 15.71% over the last week, with a monthly amount glided 61.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] stock has seen the most recent analyst activity on January 05, 2026, when Citizens JMP upgraded its rating to a Mkt Outperform but kept the price target unchanged to $8 for it. Previously, Wells Fargo downgraded its rating to Equal Weight on April 15, 2025. On April 15, 2025, downgrade downgraded it’s rating to Hold. Citizens JMP downgraded its rating to a Mkt Perform. Leerink Partners initiated its recommendation with a Market Perform and recommended $5 as its price target on September 09, 2024. CapitalOne downgraded its rating to Equal Weight for this stock on August 08, 2024, and downed its price target to $4. In a note dated January 17, 2024, Craig Hallum initiated an Buy rating and provided a target price of $21 on this stock.
Ironwood Pharmaceuticals Inc [IRWD] stock has fluctuated between $0.53 and $5.78 over the past year. Currently, Wall Street analysts expect the stock to reach $5.35 within the next 12 months. Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] shares were valued at $5.23 at the most recent close of the market. An investor can expect a potential return of 2.29% based on the average IRWD price forecast.
Analyzing the IRWD fundamentals
Ironwood Pharmaceuticals Inc [NASDAQ:IRWD] reported sales of 338.99M for the trailing twelve months, which represents a growth of 33.26%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.36%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is -0.09 and Total Capital is 0.8. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Ironwood Pharmaceuticals Inc’s Current Ratio is 1.13. On the other hand, the Quick Ratio is 1.13, and the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 2.51 and price to earnings (TTM) ratio is 33.87.
Transactions by insiders
Recent insider trading involved Silver Ronald, Principal Accounting Officer, that happened on Jan 05 ’26 when 35416.0 shares were sold. Officer, RONALD SILVER completed a deal on Jan 05 ’26 to buy 35416.0 shares. Meanwhile, Chief Commercial Officer Gaskins Tammi L sold 6016.0 shares on Nov 17 ’25.
